News

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
The additional treatment options a second opinion can provide
Empowerment comes with a second opinion. After a second opinion appointment at Karmanos Cancer Institute, patients can decide ...
Prostate Care Market Report 2025-2031 | Medtronic, Johnson & Johnson, Boston Scientific, and Abbott Laboratories Dominate through Product Innovations, Clinical Trials, M&As ...
Explore the Global Prostate Care Market's growth, projected to reach USD 69.91 billion by 2031, driven by demographic shifts, tech advances, and the rising incidence of prostate conditions. Key ...
Free Malaysia Today13h
Prostate and urinary issues? It’s best to nip it in the bud
In Malaysia, prostate cancer has been the third-most common type of cancer among men since 2012, doctors caution.
MyChesCo on MSN14h
Study Finds Most Prostate Cancer Patients Following NCCN Guidelines Live Long, Healthy Lives
New research published in the July 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network offers encouraging news for men diagnosed with nonmetastatic prostate cancer.
Psychological side effects for common prostate cancer treatment raise concerns
Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...